

Identification of Covid-19 Therapeutics and (Sars-Cov-2) Cluster Cases of India

Azhagu Madhavan S*

PG and Research Department of Zoology and Biotechnology, A Veeriya Vandayar Memorial Sri Pushpam College,
(An Autonomous Institution Affiliated to Bharathidasan University) Poondi, Thanjavur, Tamil Nadu, India

ABSTRACT

Article Info

Volume 6, Issue 3
Page Number: 01-08

Publication Issue :

May-June-2021

Article History

Accepted : 05 May 2021
Published : 30 May 2021

The COVID-19 pandemic brought about by the SARSCoV-2 has been a phenomenal worldwide wellbeing challenge. There have been 24,193,010 affirmed instances of COVID-19 around the world influencing 216 nations and 826,141 passings, as of August 27, 2020. In India, there have been 3,310,234 cases with 60,472 passings. Coronavirus, may require genuine thought treatment or even consider, the use of mechanical ventilation for patients with respiratory dissatisfaction. An intense respiratory disorder (ARDS) scene was first recognized in Wuhan, China, and later formally assigned as COVID-19 by the WHO. It is brought about by SARS-CoV-2 that is likely connected with zoonotic transmission. The clinical and hereditary qualities of SARSCoV-2 backing the comparative pathogenesis design between SARS-CoV and MERS-CoV. The raised degree of cytokine discharge during the contamination caused the disappointment of various organs prompting the patient demise. Treatment of patients relies upon the clinical course and indications related with the COVID-19. Human to human transmission through beads, tainted hands just as surfaces, has been uncovered with a brooding period differing from 2-14 days.

Keywords : SARS-CoV-2, COVID-19, 2019-nCoV, ARDS, MERS-CoV

I. INTRODUCTION

Coronavirus derivative from the Latin corona meaning “Crown” or “halo” which a refers to characteristics expression important of a crown or a solar corona approximately the virions (virus particles) Covids have a place with the Coronaviridae family in the Nidovirales request. Crown speaks to crown-like spikes on the external surface of the infection; subsequently, it was named as a Covid [1].

1.1. Coronavirus (COVID-19)

Covid ailment 2019 (COVID-19) is a rising illness with a quick increment in cases and passings since its first distinguishing proof in Wuhan, China, in December 2019. Restricted information are accessible about Covid sickness 2019 during pregnancy; in any case, data on ailments related with other exceptionally pathogenic Covids (ie, serious intense respiratory disorder and the Middle East respiratory

condition) may give experiences into Covid malady 2019's belongings during pregnancy [2]. This technology has been widely used in the field of radiology and medical imaging for research and development. Nowadays, AI plays a significant role in medical sciences by detecting or diagnosing various diseases as early as possible and even helps in treating the diseases. Coronaviruses cause illness ranging in severity from the common cold to severe respiratory illness and death [3]. The novel coronavirus eruption that we are suffering illustrates the times in which we live. There is a threat of catastrophic pandemics leading to fatalities, economic losses, and civil destabilization in the world [4]. The existing eruption would be a benchmark of how well prepared we are for such a drastic, virulent respiratory disease outbreak. COVID-19 causes a cytokine storm in the body, that is, virus-activated immune cells exude an excess of cellular hormones (cytokines) that have detrimental effects on their own tissues, endorse. Mesenchymal stem cells are a powerful immunomodulatory and anti-inflammatory agent; they normalize the function of the immune system, changed by COVID-19. Primal cell, stem cells are fundamentally a renovate system in the human body.

Imaging finding:

- ✓ During the time of admission, the patient had ill-defined bilateral alveolar consolidation with the peripheral distribution.
- ✓ After 4 hours, there were radiology reports showed worsening, with an affectation of lower lobes. Endotracheal tube and central venous line were required.
- ✓ There was bilateral alveolar consolidation, later 24 hours.
- ✓ 48 hours later, the radiology reports of her were declining. Bilateral alveolar consolidation with pan lobar affectation.
- ✓ 72 hours later, Bilateral alveolar consolidation with pan lobar affectation, with typical radiological findings of ARDS. After this, 24 hours later, she passed away.

1.2. Identification of SARS-CoV-2 cluster cases of India

Due to its genetic similarity with the severe acute respiratory syndrome (SARS) of 2003, the International Committee on Taxonomy of Viruses renamed it as SARS coronavirus 2 (SARSCoV- 2). The first case of SARS-COV-2 was reported from Kerala, India, on January 30, 20203 and since then, the numbers are increasing continuously [5].

1.3. COVID-19 in children

The child among the total number of COVID-19-affected patients was small and most children developed gentle ill health. Nearly three people were found to be infected between the ages of 20 and 64 [6].

1.4. Antiviral Western clinical treatment

Remdesivir has been accounted for as a promising antiviral tranquilize against a wide cluster of RNA infections. Holshue et al. detailed that treatment of a patient with COVID-19 with remdesivir accomplished great outcomes. Discovered that remdesivir was powerful in the control of COVID-19 in vitro. In the interim, chloroquine has been found to have safe modulatory action and could viably restrain SARS-CoV-2 in vitro [7]. Clinical controlled preliminaries have demonstrated that chloroquine was successful in the treatment of patients with COVID-19.

1.5. COVID-19 CASE DEFINITIONS

Acute respiratory sickness (fever and in any event one sign/indication of respiratory malady, e.g., hack, windedness; and requiring hospitalization) and without an elective determination that completely clarifies the clinical presentation" [8]. A plausible case is a speculate case for whom testing for the COVID-19 infection is uncertain, or testing couldn't be performed in any capacity whatsoever.

1.6. Why COVID-19-affected children manifest only mild illness?

Currently, there are no clear answers to this; there are only theories and hypotheses that are summarized below: [9]. Children from that in adults. Studies are needed to find the difference in renin angiotensin system (RAS) pathophysiology in children and adults and its possible role in determining the differential outcomes of COVID-19.

Differences in immune system of adults versus children

Immune system in children is not fully developed.

Role of childhood vaccinations

Youngsters get a few dosages of various antibodies as a component of the general vaccination program, and whether the subsequent safe incitement has any part in assurance from COVID-19 should be explained.

Role of human coronaviruses and infections in children

It requirements to pre-existing antibodies against human coronavirus infections cause ordinary cold or other respiratory virus infections or GI infections present cross-protection against COVID-19.

Role of co-infections

During H1N1 pandemic, bacterial co-disease with *Streptococcus pneumoniae* was basic which caused extensive bleakness.

II. RESULTS AND DISCUSSION

2.1. Identification of Sars-Cov-2 Cluster Cases of India

In December 2019, instances of pneumonia-like sickness because of an obscure aetiological operator were accounted for in Wuhan city, Hubei area of China. The aetiological operator was recognized as an individual from the Coronaviridae family and was named the 2019 novel Coronavirus. Because of its hereditary likeness with the extreme intense respiratory condition (SARS) of 2003, the International Committee on Taxonomy of Viruses

renamed it as SARS Covid 2 (SARSCoV-2) [10]. The primary instance of SARS-COV-2 was accounted for from Kerala, India, on January 30, 20203 and from that point forward, the numbers are expanding consistently [11]. The current investigation is a review examination of two bunches of lab affirmed Covid infection 2019 (COVID-19) patients from India and features their arrangement of functions, clinical highlights and grouping investigation [12]. The current examination is a review investigation of two bunches of research center affirmed Covid illness 2019 (COVID-19) patients from India and features their arrangement of functions, clinical highlights and grouping investigation. Individuals in close contact with a lab affirmed case and people who included embraced global travel inside the most recent 14 days and had created indications, were taken as SARS-CoV-2 suspects according to the common proposals of the Ministry of Health and Family Welfare, Government of India [13]. These cases were either conceded in the clinical wards of KGMU or other region clinics or were followed by the group of UP Integrated Disease Surveillance Program (UP-IDSP) during March 2020 [14].

2.1 Morphology

COVID-19 is caused by SARS –CoV-2 a β coronavirus who's named derives from Crown like structure in under electron microscope. It is composed of linear single stranded RNA molecule of positive (mRNA) polarity and from 28-32 kb in length [15]. Genetic material is protected by lipid bilayer and membrane proteins (M-protein) also include surface protein S-protein (spike protein) E-protein (envelop protein) the S-protein has been a focus of pathogenesis studies in mice because it appears to be the critical determinant of cell tropism, species corona [16].




Fig: 1. Morphology of SARS-CoV-2

1.2. Control and prevention of infection by COVID-19

There are numerous difficulties in avoiding contamination with the COVID 19 in the different fields including; the clinically mellow cases or atypical introductions, restricted inventory of individual defensive hardware, and or respiratory disconnection rooms at the hospitals [17]. The CDC suggests that the medical service providers should use the Personal Protective Equipment (PPE), and apply the standard, contact, and airborne safety measures, including utilization of eye insurance. Antibody created by the National Institute of Health (NIH) is in its preliminary stage in March, 2020. Besides this, the successful anticipation of COVID-19 for people necessitates defensive measures including; improving individual hygiene, wearing clinical masks, adequate rest, social distancing, and keeping rooms well ventilated [18]. There are numerous difficulties in avoiding contamination with the COVID 19 in the different fields including; the clinically mellow cases or atypical introductions, restricted inventory of individual defensive hardware, and\ or respiratory disconnection rooms at the hospitals [19]. The CDC suggests that the medical service providers should use the Personal Protective Equipment (PPE), and apply the standard, contact, and airborne safety measures, including utilization of eye insurance [20]. Added that the health workers should wear protective outfits, gloves, and either an N95 respirator in addition to confronting shields, or a fuelled air purging respirator.

III. SUMMARY AND CONCLUSIONS

3.1. Current Evidence on Covid-19

The coronavirus is rapidly spreading in the world from its origin in Wuhan City of China on 31st December 2019 to the rest of the world. Until May 10th, 2020 around 4,139,743 cases of coronavirus disease and 281,457 deaths and recovered 1,455,921 have been reported. On 9th January 2020, the WHO declared the discovery a new coronavirus, called 2019-nCoV. On 11th February 2020, the infection was named COVID-19 [21]. The infection spread through close contact with infected person. The virus includes cough and sneezing, due to presence of virus in both saliva and feces of the infected people [22]. The SARS-CoV-2 can bind to human Angiotensin-Converting Enzyme 2 (ACE-2) receptors, which are highly concentrated in salivary glands; this may be a possible explanation for the presence of SARS-CoV-2 in secretory saliva [23]. The social distancing to minimize community spread of the COVID-19, Thus, disinfection of objects and hand washing are essential for prevent the spread of this virus [24]. Preferred clinical samples for establishing the laboratory confirmation of a suspected case include swabs collected from oropharyngeal and nasopharyngeal. There is no special vaccine for this yet; the first step is to ensure adequate isolation to prevent transmission.

3.1 Evaluation of Anti Diabetic Drug Utilization in Hospitals

Observed during his study that the most prescribed drug to the patients was metformin either as monotherapy or in combination therapy [24-27]. The inclination of the prescribers is more towards combination therapy (commonly metformin and glimepiride) specially two drug therapy [28]. This was because monotherapy is mostly not sufficient for glycemic control. Though adherence to the treatment

guidelines was good but the prescribing practices need to be further improved.

3.3 Aspects of Interferons And Interleukin-6 In Diagnosis & Control of Covid- 19

Virally infected cells produce & release small protein called **Interferon** (a type of protein and glycoprotein), which plays a role in immune protection against virus. It is a group of signaling protein, made and released by host cell in response to presence of several viruses i.e. interferons causing nearby cell to heighten their anti-viral defenses. Interferon is secreted by eukaryotic cells in response to viral infection [29]. It is first line defense again viral infection but does not protect the virus infected cell that produces it [30]. When prototypic cell of origin is exposed to virus then type-1 (alpha and beta interferon) & type-2 (gamma interferon) interferon get activated. IFN-alpha detected in serum samples from subjects with viral infection. IFN- alpha, 1st FDA approved biotherapeutic treatment. Purified IFN- alpha preparation as well as IFN- alpha (level) from the stimulated cell can be analyzed by various following methods; (The reference range for total protein is typically 60-80 g/l (6-8 g/dl). However blood contains other proteins like albumin, globulin etc.).

IV. Knowledge Gaps and Research Priorities

Despite the global spread, epidemiology and clinical patterns of COVID-19 in children remain largely unclear, and emerging data indicate significant differences from adults. The psychosocial effects of closure of schools, lack of play activities and home confinement during lockdown need attention of researchers. Visual inspection of the dose-response figure in the study suggests that a parabolic relationship may be appropriate. A dose-response relationship with increased duration may happen when there is a delayed pharmacodynamic (PD) or chronopharmacologic effect (e.g., need for downstream transcription and remodelling) before clinical response. Based on the findings, there does

not appear to be a drug-disease interaction, i.e., no difference in reactions between cases and controls

V. ACKNOWLEDGEMENT

We would like to express our sincerest condolences to the patients and families who suffered from the COVID-19 outbreak. We also greatly appreciate the healthcare personnel and staff members who worked together to overcome the COVID-19 outbreak.

Funding: None.

Competing interests: None declared.

Ethical approval: Not required.

VI. REFERENCES

- [1]. World Health Organization. Coronavirus disease COVID-19). (2019).pandemic. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus->, accessed on August 27, 2020.
- [2]. Ministry of Health and Family Welfare, Government of India. COVID-19 cases in India. (2020) on August 27, Available from: <https://www.mohfw.gov.in>, accessed.
- [3]. U.S. National Library of Medicine. ClinicalTrials.gov.(2020). On June 27, Available from: <https://clinicaltrials.gov/>, accessed
- [4]. World Health Organization. Draft landscape of COVID-19 candidate vaccines. (2020), on August 27. Available from:<https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>, accessed.
- [5]. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Clinical management protocol: COVID-19. (2020) on June 27, 2020. Available from: <https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf>, accessed.

- [6]. P. Vinotha , Dr. S. Azhagu Madhavan, Ms. V. Uma. (02 - December - 2020). Title of book "Potential Antiviral Effect Of Chloroquine Against Sars-Cov-2 Remdesivir For Different Viruses". Publisher: Immortal Publications. Eternal World for Research". ISBN-. (978-93-5426-676-8).
- [7]. Y. Dong, X.Mo, Y. Hu, X. Qi, F. Jiang, Z. Jiang. (2020). Epidemiology of COVID-19 among children in China. *Pediatrics*; 145 : e20200702.
- [8]. U.S. Food & Drug Administration. Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications.(2020) on June 3, Available from: <https://www.fda.gov/media/71277/download>, accessed.
- [9]. S. Azhagu Madhavan , Senthil J, Ms. V. Uma, Ms. P. Vinotha. (13 - March - 2021). Title Of Book "Energy And Power Covid-19 Research And Development Review". Black Aviat Publishing House, India. An International Publication Agency based in India. SOCIO-ECONOMIC IMPLICATION OF COVID-19 PANDEMIC. ISBN-. (978-81-946558-0-0).
- [10]. P. Chatterjee, T. Anand, KJ. Singh, R. Rasaily, R.Singh, S.Das. (2020). Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. *Indian J Med Res*; 151 : 459-67.
- [11]. S. Azhagu Madhavan , Dr. M. Mahadevi, Dr. S. Ganesan . (29- December - 2020). Title of book "Covid -19 Clinical Features". Publisher: Xpress Publishing. An Important of Notion Press and Amazon. in. Publishing Group. ISBN-10:1637811713. ISBN-13: 978-1-63781-171-9.
- [12]. M. Majumder,. and K.D.Mandl. (2020). Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China. *SSRN Electronic Journal*. <https://doi.org/10.2139/ssrn.3524675>.
- [13]. R.; Li, W.; Lu, X.; Yang, P.; Feng, O.; Muqimova, , X. Chen and G. Wei,. (2020). Prediction of the Epidemic of COVID-19 Based on Quarantined Surveillance in China. *MedRxiv*. 2020.02.27.20027169. <https://doi.org/10.1101/2020.02.27.20027169>.
- [14]. S. Azhagu Madhavan , Dr. S. Ganesan, Dr. S. Maneemegalai, Dr. P. Vinayaga Moorthi, Dr. M. Mahadevi. (01 - April - 2021). Title of Book "Transmission Qualities And Pathogenesis Of Sars-Cov-2 And Covid-19 Infections In Humans Therapeutics & Recent Developments In Current Evidence Reviews". HOSPITALITY AND TOURISM INDUSTRY AMID COVID -19 PANDEMIC. Team Hospitality Treasure – Eureka Publications. (A Division of EnTo Tech Pvt. Ltd.) India Office: 604, The Poorva, Pimple Saudagar, Pune, Maharashtra – 411027. First Edition – 2021. ISBN-. (978-81-951936-0-8). [Scopus book chapter publication].
- [15]. S. Azhagu Madhavan , Vinotha P2, Uma V3 and Mahadevi M4, 2020. Covid-19 Therapeutics & Recent Developments In Current Evidence Reviews. *International Research Journal of Modernization in Engineering Technology and Science*. Volume: 02/Issue: 09/September -2020. E-ISSN: 2582-5208.
- [16]. WHO, Coronavirus disease (COVID-19) pandemic, (2020). <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (accessed August 1, 2020).
- [17]. J. de Vos, The effect of COVID-19 and subsequent social distancing on travel behavior, *Transp. Res. Interdiscip. Perspect.* 5 (2020) 100121, doi: 10.1016/j.trip.2020.100121.
- [18]. S. Azhagu Madhavan , Dr. S. Ganesan, Ms. P. Vinotha, Ms. V. Uma, Dr. M. Mahadevi, Dr. J. Senthil. (01 - April - 2021). Title of book "Immune System Might Promote Recovery For Mild Covid-19 Patients Impact Of Coronavirus On Education In India Review". HOSPITALITY AND TOURISM INDUSTRY AMID COVID -19 PANDEMIC. Team Hospitality Treasure –Eureka Publications. (A

- Division of EnTo Tech Pvt. Ltd.) India Office: 604, The Poorva, Pimple Saudagar, Pune, Maharashtra – 411027. First Edition – 2021. ISBN-. (978-81-951936-0-8). [Scopus book chapter publication].
- [19]. V. Uma, Dr. S. Azhagu Madhavan , Ms. P. Vinotha. (17 - November - 2020). Title Of Book “Sars-Cov-2 Infection Among Healthcare Workers In India Clinical & Epidemiological Implications”. Publisher: Academia. India & Covid -19: Multi-dimensional Perspective”. (APH PUBLISHING CORPORATION, 4425-36/7, Ansari Road, Darya Ganj, New Delhi. Pin 11002. ISBN-. (978-93-89875-59-1).
- [20]. J.Zhang, M.Litvinova,Y. Liang Y, Wang, W.Wang, S. Zhao. (2020). Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science*; 368 : 1481-6.
- [21]. ML, Choudhary, V. Vipat, S. Jadhav, A. Basu, S. Cherian, P. Abraham., (2020). Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India. *Indian J Med Res*; 151 : 251-4.
- [22]. S. Azhagu Madhavan , Mahadevi M2, Vinotha P3, Uma V4, and Ganesan S1, From 29-31, January 2021. People Preferences in Selection of Hospital during Covid-19 Impact on Personal Life Review. Online International Conference on Recent Advances in Deep Learning (ICRADL-2021). Organized by the Department of Computer Science and Engineering of Shri Vishnu Engineering College for Women (A), Bhimavaram, AP. (IJERT. Journal). ICRADL - 2021 Conference Proceedings Volume 9, Issue 5, Special Issue - 2021 [ISSN: 2278-0181].
- [23]. D. Tomasi, (2020). Coronavirus Disease (COVID-19). A Socio-epidemiological Review. *Vermont Academy of Arts and Sciences*. 1: 1-7.
- [24]. N.Gupta, S. Agrawal, P.Ish, S.Mishra, R.Gaind, G.Usha. (2020). Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. *Monaldi Arch Chest Dis*; 10 : 90.
- [25]. S. Azhagu Madhavan , Ganesan Sa, Mahadevi Mb, Vinotha Pc, Uma Vc, Senthil Jd. 2021. Medical and Healthcare Effective Therapeutic and Covid-19 Role of Herbal Medicine in the Treatment Review. *Bulletin of Environment Pharmacology and Life Sciences*. (09 March 2021). ISSN: 2277-1808.
- [26]. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. (2020) accessed on June 27, Available from: <https://covid19treatmentguidelines.nih.gov/>.
- [27]. SL,. Arnold and F. Buckner. (2020).Hydroxychloroquine for treatment of SARS-CoV-2 Infection? Improving our confidence in a model-based approach to dose selection. *Clin Transl Sci*; 13 : 642-5.
- [28]. S. Azhagu Madhavan , Ms. P. Vinotha, Ms. V. Uma. (17 - November - 2020). Title of book “Therapeutic Preferences For Coronavirus (Sars-Cov-2) Patients And Current Evidence On Covid-19”. Publisher: Academia. India & Covid -19: Multi-Dimensional Perspective”. (Aph Publishing Corporation, 4425-36/7, Ansari Road, Darya Ganj, New Delhi. Pin 11002. Isbn-. (978-93-89875-59-1).
- [29]. C, Smit, MYM, Peeters JN. van den Anker, CA. Knibbe. (2020). Chloroquine for SARS-CoV-2: Implications of Its unique pharmacokinetic and safety properties. *Clin Pharmacokinet*; 59 : 659-69.
- [30]. S. Azhagu Madhavan , Vinotha P2, Uma V3, Ganesan S4, Senthil J5. 2020. COVID-19 therapeutic and prevention aminoquinolines against coronavirus disease (COVID-19): chloroquine or hydroxychloroquine review. *The International Journal of Indian Psychology* ISSN 2348-5396 (Online) / ISSN: 2349-3429 (Print) Volume 8, Issue 3, July- Sep, 2020.

Cite this article as :

Azhagu Madhavan S, "Identification of Covid-19 Therapeutics and (Sars-Cov-2) Cluster Cases of India", International Journal of Scientific Research in Chemistry (IJSRCH), ISSN : 2456-8457, Volume 6 Issue 4, pp. 01-08, July-August 2021.
URL : <https://ijsrch.com/IJSRCH21631>